These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26132570)

  • 1. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.
    Rau D; Lang M; Harth A; Naumann M; Weber F; Tumani H; Bayas A
    Int J Mol Sci; 2015 Jun; 16(7):14669-76. PubMed ID: 26132570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
    Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
    Buonomo AR; Saccà F; Zappulo E; De Zottis F; Lanzillo R; Gentile I; Carotenuto A; Borgia G; Russo CV
    Mult Scler Relat Disord; 2019 Jan; 27():44-45. PubMed ID: 30316174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies.
    Holmøy T; von der Lippe H; Leegaard TM
    BMC Neurol; 2017 Apr; 17(1):65. PubMed ID: 28376817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab treatment of multiple sclerosis.
    Coles AJ
    Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab therapy for multiple sclerosis.
    Coles AJ
    Neurotherapeutics; 2013 Jan; 10(1):29-33. PubMed ID: 23184314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
    Mori M
    Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
    Ruck T; Bittner S; Wiendl H; Meuth SG
    Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outlook for alemtuzumab in multiple sclerosis.
    Williams T; Coles A; Azzopardi L
    BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations.
    Dörr J; Baum K
    Drug Des Devel Ther; 2016; 10():3379-3386. PubMed ID: 27799738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab for Multiple Sclerosis.
    Willis MD; Robertson NP
    Curr Neurol Neurosci Rep; 2016 Sep; 16(9):84. PubMed ID: 27485945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
    Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
    Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
    Prescrire Int; 2015 Mar; 24(158):69. PubMed ID: 25897458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alemtuzumab: a further option for treatment of multiple sclerosis].
    Menge T; Kieseier BC; Warnke C; Aktas O; Hartung HP
    Nervenarzt; 2012 Apr; 83(4):487-501. PubMed ID: 22038387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graves' disease after treatment with alemtuzumab for multiple sclerosis.
    Tsourdi E; Gruber M; Rauner M; Blankenburg J; Ziemssen T; Hofbauer LC
    Hormones (Athens); 2015; 14(1):148-53. PubMed ID: 25402383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
    Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
    Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
    Aguirre C; Meca-Lallana V; Sánchez P; Vivancos J
    Mult Scler Relat Disord; 2019 Oct; 35():270-271. PubMed ID: 31442904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies].
    Klotz L; Meuth SG; Kieseier B; Wiendl H
    Nervenarzt; 2013 Aug; 84(8):984-94. PubMed ID: 23793409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.